Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Jeremy Hamm's publication output changed over time?
ScholarIQpublication output · 2012–2023
Output grew0% over the shown period — from 1 works in 2012 to 1 in 2023.
1
1
1
3
3
1
1
2012201320152016201720222023
What are the most-cited papers on Jeremy Hamm?
ScholarIQmost cited works
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
William Morris, Scott Tyldesley, S. Rodda, Ross Halperin, Howard Pai, Michael McKenzie, Graeme Duncan, Gerard Morton, Jeremy Hamm, Nevin Murray
International Journal of Radiation Oncology*Biology*Physics. 2016736 Citations
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
Sree Rodda, Scott Tyldesley, William Morris, Mira Keyes, Ross Halperin, Howard Pai, Michael McKenzie, Graeme Duncan, Gerard Morton, Jeremy Hamm, Nevin Murray
International Journal of Radiation Oncology*Biology*Physics. 2017318 Citations
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
S. Rodda, William Morris, Jeremy Hamm, Graeme Duncan
International Journal of Radiation Oncology*Biology*Physics. 201798 Citations
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.
William Morris, Scott Tyldesley, Howard Pai, Ross Halperin, Michael McKenzie, Graeme Duncan, Gerard Morton, Nevin Murray, Jeremy Hamm
Journal of Clinical Oncology. 201596 Citations
An Updated Analysis of the Survival Endpoints of ASCENDE-RT
Justin Oh, Scott Tyldesley, Howard Pai, Michael McKenzie, Ross Halperin, Graeme Duncan, Gerard Morton, Mira Keyes, Jeremy Hamm, William Morris
International Journal of Radiation Oncology*Biology*Physics. 202262 Citations
Related on ScholarIQ
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
Paper
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
Paper
ASCENDE-RT: An Analysis of Health-Related Quality of Life for a Randomized Trial Comparing Low-Dose-Rate Brachytherapy Boost With Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
Paper
ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer.
Paper
An Updated Analysis of the Survival Endpoints of ASCENDE-RT
Paper
Incomplete testosterone suppression with luteinizing hormone‐releasing hormone agonists: does it happen and does it matter?
Paper